Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsored by: |
Eli Lilly and Company |
---|---|
Information provided by: | Eli Lilly and Company |
ClinicalTrials.gov Identifier: | NCT00034463 |
This is a non-randomized, phase 1, study with the primary objective of determining the toxicities and establishing the maximum tolerated dose of ALIMTA when administered as a 10 minute infusion every 21 days with folic acid or multi-vitamin supplementation therapy in lightly or heavily pre-treated patients with locally advanced or metastatic cancer.
Condition | Intervention | Phase |
---|---|---|
Metastases Cancer |
Drug: ALIMTA Drug: folic acid Drug: multi-vitamins |
Phase I |
Study Type: | Interventional |
Study Design: | Treatment |
Official Title: | A Phase 1 Trial of ALIMTA (Pemetrexed) in Patients With Locally Advanced or Metastatic Cancer |
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
United States, Texas | |
For additional information regarding investigative sites for this trial, contact the Clinical Trials Support Center at 1-877-CTLILLY (1-877-285-4559) or speak with your personal physician. | |
San Antonio, Texas, United States |
Study ID Numbers: | 1310, H3E-MC-JMAS |
Study First Received: | April 29, 2002 |
Last Updated: | July 18, 2006 |
ClinicalTrials.gov Identifier: | NCT00034463 |
Health Authority: | United States: Food and Drug Administration |
metastatic cancer chemotherapy |
Pemetrexed Folic Acid Neoplasm Metastasis |
Antimetabolites Antimetabolites, Antineoplastic Vitamin B Complex Molecular Mechanisms of Pharmacological Action Hematinics Antineoplastic Agents Growth Substances Physiological Effects of Drugs Hematologic Agents |
Enzyme Inhibitors Folic Acid Antagonists Pharmacologic Actions Neoplastic Processes Neoplasms Pathologic Processes Vitamins Therapeutic Uses Micronutrients |